Françoise Audat
Necker-Enfants Malades Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Françoise Audat.
Clinical Autonomic Research | 2004
Pascal Leonetti; Françoise Audat; Arlette Girard; Dominique Laude; François Lefrère; Jean-Luc Elghozi
Abstract.Rate-controlled blood withdrawal was used to reduce cardiac preload and consequently stroke volume in patients with normal cardiac function. Twelve patients with asymptomatic hereditary hemochromatosis, undergoing regular phlebotomy therapy, volunteered for the study. An average volume of 375 ml was withdrawn in an average period of 6.4 min. Finger pressure was continuously measured by a Finometer® device which includes the Beatscope® software for deriving the stroke volume from the blood pressure waveform. Blood withdrawal resulted in reduction of the stroke volume estimates (from 94.0 ± 5.2 to 80.7 ± 5.3, P < 0.05) together with a reduced pulse pressure (from 53.0 ± 3.5 to 47.1 ± 3.2, P < 0.05). No significant changes in heart rate (75.2 ± 3.7 versus 78.3 ± 4.5 beats/min) were observed. Calculated cardiac output was reduced while calculated total peripheral resistance was elevated after blood withdrawal. Beat-to-beat analysis demonstrated a significant linear regression between most of the hemodynamic indices and the volume withdrawn. The highest correlation coefficients were found for the stroke volume (0.88 ± 0.01, P < 0.001) and the pulse pressure (0.80 ± 0.04, P < 0.001) corresponding also to the highest slopes for the lines relating these measures to the relative blood volume withdrawn. The non-invasive estimation of finger blood pressure can be used to derive simple on-line indices (pulse pressure, stroke volume using the Modelflow) of cardiac preload, which are of major interest in the monitoring of cardiovascular status.
Vox Sanguinis | 1996
M.N. Mayer; Mariane de Montalembert; Françoise Audat; M.C. Brusset; B. Houfani; J. Merckx; G. Barrier; Claire Gazengel
To determine whether autologous blood donation can be used safely and efficiently in children weighing 8–25 kg, we studied children whose perioperative blood losses were expected to exceed 25% of total blood volume. Blood donations were performed in pediatric units, under the direction of an anesthesiologist and a blood bank physician experienced in pediatric care. Twenty‐four children, median age 6 years (1–13), were included. They underwent surgery mainly for digestive or urological disorders, and for orthopedic defects. Forty blood collections were performed of the 46 prescribed. Phlebotomies could not be performed in 1 child because of the mothers apprehension, and in 5 cases because of venous access problems. All phlebotomies were hemodynamically well tolerated. Hemodilution was also performed in 17 children, and cell saver used in 2. Allogeneic blood transfusion was avoided in 21/24 children.
Bone Marrow Transplantation | 2006
François Lefrère; S Zohar; David Ghez; Richard Delarue; Françoise Audat; F Suarez; Olivier Hermine; G Damaj; N Maillard; J A Ribeil; M Azagury; R Misbahi; K Jondeau; Marina Cavazzana-Calvo; L Dal Cortivo; Bruno Varet
A study was conducted to compare the efficiency and toxicity of two peripheral blood stem cell (PBSC) mobilization procedures for newly diagnosed patients with multiple myeloma. Patients from group 1 (n=51) were treated by high-dose cyclophosphamide (HD-CY) plus G-CSF (5 μg/kg/day), and the second group (n=31) by VAD regimen plus G-CSF administration (10 μg/kg/day). Successful mobilization, defined by a minimal count of 2.5 × 106 CD34+ cells/kg collected, was achieved in 96 and 90% of patients in groups 1 and 2, respectively (P=0.15). The mean peripheral blood CD34+ cells concentration and the mean CD34+ cells/kg collected were higher in group 2 than in the group 1 (P=0.05). The mean number of leukaphereses necessary to collect a count of 2.5 × 106 CD34+ cells/kg was reduced in group 2 compared to group 1. Adverse events, blood products consumption and time spent in the hospital were significantly greater after HD-CY. In conclusion, VAD plus a G-CSF dose of 10 μg/kg administration seems preferential to HD-CY plus a G-CSF dose of 5 μg/kg for PBSC collection because of equivalent or better efficiency in stem cell mobilization, strong favorable toxicity profile and reduced cost.
Transfusion | 2007
François Lefrère; Sarah Zohar; Sandrine Beaudier; Françoise Audat; Jean-Antoine Ribeil; David Ghez; Bruno Varet; Marina Cavazzana-Calvo; Liliane Dal Cortivo; Remi Letestu; Elizabeth McIntyre; Chantal Brouzes
BACKGROUND: Quantification of peripheral blood (PB) CD34+ cells is commonly used to plan peripheral blood progenitor cell (PBPC) collection but is time‐consuming. Sysmex has developed a hematology analyzer that can quickly identify a population of immature hematopoietic cells (HPCs) according to cell size, cell density, and differential lysis resistance, which may indicate the presence of PBPCs in PB. This prospective study has evaluated the potential of such method to predict the PBPC mobilization.
Leukemia & Lymphoma | 2007
Rémi Letestu; Christophe Marzac; Françoise Audat; Ramdane Belhocine; Sylvie Tondeur; Véronique Baccini; Loïc Garçon; Liliane Dal Cortivo; Jean-Yves Perrot; François Lefrère; Françoise Valensi; Florence Ajchenbaum-Cymbalista
Successful peripheral blood stem cell (PBSC) collection depends on the timing of apheresis based on CD34+ cell enumeration. Because this analysis is expensive and induces organization difficulties, we evaluated hematopoietic progenitor cell (HPC) quantification on the Sysmex XE-2100 as a surrogate analysis. We tested 157 blood samples for CD34+ cells and HPC counts. We found a good linear correlation between HPC and CD34+ and determined simple rules allowing to use HPC count in daily practice. We set a positive cut-off >30 HPC/mm3 for allowing PBSC harvest and a negative cut-off at 0 HPC/mm3 for which collection should be delayed. These two situations accounted for 62% of cases and CD34+ cell count by flow cytometry confirmed HPC result in 95% of cases. Between 0 and 30 HPC/mm3, CD34+ enumeration is required for decision-making. We conclude that HPC count may be a useful surrogate for CD34+ enumeration in PBSC harvest monitoring.
British Journal of Haematology | 2006
Claire Booth; J.-A. Ribeil; Françoise Audat; Liliane Dal-Cortivo; Paul Veys; Adrian J. Thrasher; E. Graham Davies; François Lefrère; Alain Fischer; Marina Cavazzana-Calvo; H. Bobby Gaspar
Haematopoietic stem cell transplantation can be limited by ineffective haematopoiesis and poor immune recovery. A CD34+ cell infusion without conditioning has the potential to improve stem cell function with limited toxicity. Eighteen patients with congenital immunodeficiencies received CD34+ boosts for various defects. When given <1 year after the original graft, six of seven cytopenic patients achieved transfusion independence. A second cohort (n = 11) received boosts >1 year after the original graft; only minimal changes in immune function or chimaerism were noted. Unconditioned stem cell boosts have limited toxicity but should be given early after the original graft to be effective.
British Journal of Haematology | 1996
Buzyn-Veil A; Coralie Belanger; Françoise Audat; Olivier Hermine; C. Bodemer; Vincent Ribrag; Isabelle Radford; Hélène Poirel; Catherine Chane; Françoise Valensi; E Macintyre; Bruno Varet
Therapeutic options for treatment of recurrence of leukaemia after allogeneic bone marrow transplantation (BMT) are limited. A beneficial effect of donor lymphocyte infusions (DLI) has not previously been described in acute myeloid leukaemia (AML) relapse. We report a case of AML with t(8;21), relapsing 3 months after BMT, who received DLI without adjuvant chemotherapy or growth factors. The patient developed acute GVHD and achieved a rapid complete remission of his AML by both cytologic and molecular criteria of at least 14 months duration, thereby showing that DLI for AML in relapse after BMT is an alternative therapeutic option.
Vox Sanguinis | 1997
Laurence Morand-Joubert; Daniel Vittecoq; F. Roudot-Thoraval; Martine Mariotti; François Lefrère; Farad Heshmati; Françoise Audat; Patrick Lambin; Françoise Barré-Sinoussi; Jean-Jacques Lefrère
Background and objectives: In human immunodeficiency virus (HIV) infections, passive immunotherapy can be carried out through infusions of virus‐inactivated plasma from symptomless HIV‐infected persons with abundant HIV antibodies. Materials and methods: We carried out a prospective, randomized, double‐blind, controlled, passive immunotherapy study, which compared two groups. One received plasma rich in HIV antibodies, the other a standard seronegative plasma. Results: Measurement of the plasma HIV RNA load showed in both groups a significant decrease in the mean viral copy number at the end of the first month, followed by an increase at the third month. Beyond the third month, a significant decrease in viral load was observed only in the treatment group. A significant difference in favor of the treatment group was observed for plasma viremia by HIV culture. For the cytokines involved in the viral replication and for the immune activation markers such as neopterin and β2‐microglobulin, the biological analysis in plasma failed to show a significant difference in either group. Clinically, the treatment group benefited by delay in the appearance of the first AIDS‐defining event and reduction in the cumulative incidence of such events. Conclusion: One possible interpretation is that passive immunotherapy affects plasma viral load, but there is no evidence that HIV‐specific antibodies are exclusively responsible for the observed effects.
Transfusion | 2002
François Lefrère; Richard Delarue; Dominique Somme; Vincent Levy; Gandhi Damaj; Angela Tu; Raphael Porcher; Françoise Audat; Claire Boulat; Marine Cavazzana‐Calvo; Agnès Buzyn; Coralie Belanger; Natacha Maillard; Olivier Hermine; Bruno Varet
BACKGROUND: No agreement exists about the number of autologous peripheral blood progenitor cells (PBPCs) to transfuse for optimal hematologic recovery after high‐dose chemotherapy.
Transfusion | 1996
Jean-Jacques Lefrère; F. Roudot-Thoraval; D. Vittecoq; F. Heshmati; Françoise Audat; J. Lerable; D. Reed; J. C. Petit; B. Burghoffer; Laurence Morand-Joubert
BACKGROUND: Passive immunotherapy in human immunodeficiency virus (HIV) infection is based on transfusions of plasma that is rich in HIV antibodies. STUDY DESIGN AND METHODS: To verify whether the clearance of transfused antibodies will maintain an elevated titer of specific antibodies between biweekly transfusions of plasma, the titers of anti‐ HIV‐1 in plasma and in transfusion recipients were measured. Samples from 12 recipients were analyzed by automated scanning of Western blot, before transfusion and at Days 2, 7, and 14 after transfusion. RESULTS: The p24 antibody became detectable or higher than the baseline after transfusion and remained detectable until the second transfusion. Anti‐ p24 titers were variable and dependent on the antibody titer of the transfused plasma and the baseline p24 antigen titer. CONCLUSION: Biweekly transfusion of plasma with a high anti‐HIV titer maintains a high anti‐p24 titer between transfusions in AIDS patients treated with passive immunotherapy.